Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 96, Issue 2, Pages 136-143
Publisher
Wiley
Online
2015-04-02
DOI
10.1111/ejh.12558
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)
- (2014) A. Jaccard et al. HAEMATOLOGICA
- Still no certainty about the role of upfront bortezomib among patients with AL amyloidosis
- (2014) A Dispenzieri LEUKEMIA
- Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients
- (2014) G Palladini et al. LEUKEMIA
- A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis
- (2014) C P Venner et al. LEUKEMIA
- Systemic light chain amyloidosis: an update for treating physicians
- (2013) G. Merlini et al. BLOOD
- Allaying and alleviating amyloid agony and anxiety
- (2013) M. A. Gertz BLOOD
- A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
- (2013) A. D. Wechalekar et al. BLOOD
- Light chain amyloidosis 2012: a new era
- (2013) Moshe E. Gatt et al. BRITISH JOURNAL OF HAEMATOLOGY
- Light chain amyloidosis: the heart of the problem
- (2013) G. Merlini et al. HAEMATOLOGICA
- Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach
- (2013) G. Palladini et al. HAEMATOLOGICA
- Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis
- (2013) Taxiarchis V. Kourelis et al. JOURNAL OF CLINICAL ONCOLOGY
- CyBorD: stellar response rates in AL amyloidosis
- (2012) G. Merlini BLOOD
- Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
- (2012) J. R. Mikhael et al. BLOOD
- Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
- (2012) C. P. Venner et al. BLOOD
- New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
- (2012) Giovanni Palladini et al. JOURNAL OF CLINICAL ONCOLOGY
- Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
- (2012) R L Comenzo et al. LEUKEMIA
- Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma
- (2011) Constantine S. Mitsiades et al. JOURNAL OF CLINICAL ONCOLOGY
- Amyloidosis: Pathogenesis and New Therapeutic Options
- (2011) Giampaolo Merlini et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis
- (2010) W. Lamm et al. ANNALS OF HEMATOLOGY
- I don't know how to treat amyloidosis
- (2010) M. A. Gertz BLOOD
- Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
- (2010) Efstathios Kastritis et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma
- (2010) Sumit Madan et al. MAYO CLINIC PROCEEDINGS
- Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
- (2008) A. D. Wechalekar et al. HAEMATOLOGICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now